-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
TMO delivered Q1 top- and bottom-line beats with adjusted EPS of $5.44 vs. the $5.15 consensus and revenue of $11.01B (+6% Y/Y), though organic growth remained modest at 1% as the $8.9B Clario acquisition contributed significantly to performance. Mixed segment performance showed Life Sciences Solutions strength at $2.64B (+13% Y/Y) with improved 36.2% margin benefiting from the Solventum acquisition, while Analytical Instruments faced flat revenue and significant margin compression to 20.7% from 23.2% the prior year reflecting ongoing equipment spending pressures. FCF surged to $825M from $373M, supporting return of capital to shareholders. TMO returned $3.0B through share repurchases and increased its dividend 10%. The company plans to update 2026 financial guidance during the upcoming earnings call. We believe the robust cash flow performance and disciplined capital allocation activities support TMO's operational resilience despite the challenging life sciences tools operating environment.